Videos

Chang described how the ASCRS Functional Vision Working Group is proposing a structured framework centered on visual quality, visual range, and visual symptoms to guide lens classification.

Andrew G. Lee, MD, and Drew Carey, MD, review how clinical and imaging findings relate to vision recovery after radiotherapy for optic nerve sheath meningioma.

Their discussion touches upon EyeSustain’s global efforts to reduce waste in ophthalmology, strategies for greener cataract surgery, and collaborations with industry and professional societies to promote sustainability.

In this third case, Dr. Maria Berrocal describes a patient with highly cystic diabetic macular edema (DME) in the left eye who had shown minimal response to two prior steroid injections.

Pitha discusses how ophthalmic drug shortages — more frequent and longer-lasting than the national average — are threatening adherence to glaucoma therapy.

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including Medicare coverage limitations, out-of-pocket costs, and the role of assistance programs such as Good Days in expanding treatment access.

Dhoot discusses the full results of the 5-year GALE extension study of pegcetacoplan in patients with GA secondary to age-related macular degeneration.

In this second case, Dr. Maria Berrocal presents a patient with severe, refractory diabetic macular edema (DME) who had received 13 prior anti-VEGF injections (bevacizumab and aflibercept) with persistent fluid and legal blindness (20/200 vision).

Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, consider how emerging treatments impact patient vision, functional outcomes, and practical management of geographic atrophy.

In this opening segment, Dr. Maria Berrocal introduces a case-based discussion on real-world management of diabetic macular edema (DME), with a focus on improving retinal drying, extending durability, and reducing patient burden.

Take a look at some, but certainly not all, that you may have missed from this year’s EnVision Summit.

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

Join Douglas D. Koch, MD, and Liliana Werner, MD, PhD, as they break down acrylic and silicone intraocular lenses, discuss material-specific risks, and explore the future of lens technology in this inaugural episode.

Zarmeena Vendal, MD, discussed the intersections between cataract surgery and glaucoma.

Inder Paul Singh, MD, discusses his practice's approach to office-based surgery.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

Bonnie An Henderson, MD, founder of EnVision Summit, highlights how the annual conference integrates MD and OD tracks, practical subspecialty updates, and structured opportunities for connection across career stages.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and clinicians globally and locally.

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment burden and shift retinal disease management toward longer-acting, maintenance-based approaches.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.